DeMane, the former COO at Medtronic, will keep an active role in Nevro, which he joined in 2011 after a quickly aborted stint at the head of Lanx. He’s due to leave the corner office June 1, Nevro said.
“As a result of Michael’s outstanding leadership, Nevro has become 1 of the most successful medtech companies of the past decade. Speaking on behalf of the entire board, we wish to thank Michael for his insightful vision and guidance over the past 5 years and we look forward to his continued leadership at the board level. We are confident that the strong and capable management team Michael has assembled will continue to execute Nevro’s growth strategy in an exemplary way,” former chairman Frank Fischer said in prepared remarks.
“Rami is an exceptional executive, and he has had a critically important role in building Nevro into what it is today,” DeMane added. “This is a deliberate and thoughtful succession process, in which I have worked closely with the Nevro board of directors to ensure a seamless transition. The board and I are absolutely confident in Rami’s ability to lead this remarkable organization into the future.”
Cardiovascular Systems CEO Martin steps down to focus on cancer fight
Cardiovascular Systems (NSDQ:CSII) CEO David Martin resigned to focus on his battle against cancer, the company said this week. Martin, whose diagnosis was revealed last September, took a 3-month leave Dec. 1 to undergo further treatment, including chemotherapy.
Lightstone Ventures taps ev3 vet Enxing Seng
Lightstone Ventures said it tapped Stacy Enxing Seng as a venture partner. Enxing Seng, a former co-founder at ev3 and ex-president of Covidien’s vascular therapies division, is on the boards of Hill-Rom Holdings (NYSE:HRC), Sonova Holding AG (SIX:SOON), Solace Therapeutics and Spirox.